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Abstract 
Background: Hemodialysis catheter-related bacteremia (HD CRB) is a major com-
plication of long-term hemodialysis (HD) therapy and bacteremia is secondary only 
to cardiovascular disease as the leading cause of death in patients receiving renal re-
placement therapy. A large part may be preventable and surveillance is a critical as-
pect of infection control and prevention. Aim: To analyze incidence, causative spe-
cies, and treatment of HD CRB in adult chronic HD patients at Nordsjaellands Hos-
pital (NOH), Denmark. Methods: All episodes of bacteremia in the Department of 
Cardiology, Nephrology and Endocrinology (KNEA), NOH from 2010 to 2013 were 
analyzed. Inclusion criteria: Adult chronic HD patients with a tunneled dialysis ca-
theter diagnosed with HD CRB. Causative microorganism and antimicrobial treat-
ment were recorded for each episode. Findings: Ninety-nine episodes of HD CRB in 
72 patients were found with a mean incidence rate of 0.9/1000 catheter-days. Gram- 
positive bacteria were isolated in 71% of the episodes, gram-negative bacteria in 25%, 
both in 3%, and yeast in 1%. The most frequently isolated microorganisms were Sta-
phylococcus aureus (33%), Coagulase-negative staphylococci (29%), enterobacteria-
ceae (20%) and enterococci (8%). The most commonly used empiric antimicrobials 
were cefuroxime and vancomycin and the overall efficacy was 77%. Conclusion: The 
well-functioning infection prevention strategy seems to be successful resulting in a 
relatively low incidence rate of HD CRB compared with that shown in international 
studies. The high proportion of gram-negative bacteria raises the question as to 
whether future antimicrobial guidelines should cover both gram-positive and gram- 
negative bacteria. 
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1. Introduction 
Bacteremia is a serious condition associated with substantial morbidity and a high short- 
term mortality rate [1] [2] [3] [4]. In Denmark, about 35% of the bacteremic episodes 
are nosocomial and approximately 20% are health-care acquired (patients with a hos-
pital stay in the 30 days before hospital admission or who have regular hospital visits 
(e.g. for hemodialysis (HD) or chemotherapy)) [3]. This means that a large part of this 
serious problem may be preventable; consequently, focus on establishing an effective 
infection prevention strategy is paramount. 
Patients with end-stage renal disease receiving chronic HD through a central venous 
catheter (CVC) are more susceptible to bacteremia than others, due to the direct access 
to the bloodstream, several comorbidities and an impaired immune system. 
In 2013 approximately 2000 patients received chronic HD treatment in Denmark [5]. 
International studies have shown that the incidence rate of HD catheter-related blood-
stream infections (CRBSI) is between 0.45 and 5.5 episodes per 1000 catheter-days and 
the hazard ratio for bacteremia in patients with tunneled CVCs compared with patients 
with native arterio-venous (AV) fistulas is approximately 5 [6]-[11]. 
Interventions proven to be effective in reducing the incidence rate of catheter-related 
bacteremia in HD patients are: surveillance, good hand hygiene, hygiene audits, aseptic 
techniques, staff and patient education, and reduction in the number of HD catheters 
[12] [13] [14].  
Nevertheless, it is estimated that almost 30% of HD patients depend on CVCs as 
their primary vascular access and for some of these patients the use of HD catheters is 
unavoidable [13] [15]. 
The aim of this study was to analyze incidence, causative species, and treatment of 
hemodialysis catheter-related bacteremia (HD CRB) in adult chronic HD patients at 
Nordsjaellands Hospital (NOH), Denmark from 2010-2013. 
2. Methods 
2.1. Study Design 
A single center, retrospective, quality study performed on adult chronic HD patients 
diagnosed with HD CRB in Department of Cardiology, Nephrology and Endocrinology 
(KNEA), NOH from 2010 to 2013. 
Approximately 150 patients at NOH are on chronic HD treatment and approximately 
40% have a tunneled CVC [5]. 
2.2. Study Population 
All cases of bacteremia in KNEA, NOH from 2010-2013 were screened by reviewing the 
unitary electronic health records (EHR). Eligible patients were aged ≥18 years, on 
chronic HD through a tunneled CVC and diagnosed with HD CRB in the study period. 
Patients receiving HD trough another type of vascular access or with other sources of 
infection were excluded.  
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2.3. Data Collection 
The EHR of the identified patients were reviewed by a nephrologist at NOH and clini-
cal and demographic variables were recorded in a database. The following variables 
were collected: civil registration number [16], age, name, sex, vascular access type (HD 
catheter/AV fistula/graft), catheter type (permanent/acute), date of positive blood sam-
ple collection, location of blood sample collection, and type of microorganism isolated. 
Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of 
Copenhagen, routinely identified the microorganisms cultured from blood and per-
formed antibiotic susceptibility testing. The antibiograms were retrospectively retrieved 
and analyzed in December 2014. 
Information on the antimicrobial treatment was retrieved from the EHR, which in-
clude an electronic medication module. Antimicrobial treatment was analyzed in rela-
tion to the antibiograms of the microorganisms isolated from blood cultures. 
2.4. Study Definitions 
A chronic HD patient was defined as a patient on HD through a tunneled permanent 
CVC. A blood culture typically includes four vials taken from the catheter and/or four 
vials taken from a peripheral vein (two aerobe and two anaerobe, respectively). 
An episode of HD CRB was defined as a positive blood culture with a bacterial or 
fungal isolate taken from the CVC or a peripheral vein of a patient on chronic HD 
therapy with no other identified source of infection. An episode was considered poly-
microbial if more than one microorganism was isolated from the blood on the same 
date. Two episodes of HD CRB in the same patient were defined as two separate posi-
tive blood cultures with different microorganisms taken at intervals of more than 24 
hours or two positive blood cultures with the same isolated microorganism taken at an 
interval of more than 28 days. 
The empiric antimicrobials were defined as all antimicrobials given before knowing 
the species of the isolated microorganisms. The empiric treatment was considered ef-
fective if all bacteria/fungi cultured from the blood were susceptible to one or more of 
the given empiric antimicrobials. 
All episodes were considered as health-care associated infections (HCAI) according to 
the definition from Friedman et al. and the European Centre for Disease Prevention 
and Control (ECDC) [17] [18]. 
2.5. Outcome 
The outcomes of the study were the incidence rate of HD CRB per 1000 catheter-days, 
the frequencies of the different bacterial/fungal isolates and the efficacy of the empiric 
antimicrobials. 
2.6. Statistical Analysis 
The incidence rate of HD CRB per 1000 catheter-days was calculated for each quarter 
in the four-year study period. 
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Catheter-days is an estimate found by counting the number of tunneled catheters in 
use per quarter and multiplying it by the number of days in the quarter. 
Data are presented as median, range and interquartile range (IQR). Frequency dis-
tribution is presented as histograms and a pie diagram. Fisher’s exact test was used for 
comparison of microbial isolates in men and women, p < 0.05 was considered signifi-
cant. 
2.7. Ethics 
The study was approved by the Regional Scientific Ethics Committee (H-2-2014-FSP-73). 
3. Results 
3.1. Patient Characteristics 
We identified 72 patients with HD CRB; 48 (67%) were male and the patients had a 
median age of 66 years (IQR 52 - 71 years). Of those identified, 55 (76%) had one epi-
sode of HD CRB in the study period, 10 (14%) had two episodes, five (7%) had three 
episodes and two (3%) had more than three episodes (one patient had four and one pa-
tient had five episodes). 
3.2. Incidence Rates 
The mean incidence rate of HD CRB was 0.9 episodes/1000 catheter-days (range: 0.1 - 
1.6). The incidence rate was stable during the study period with the lowest incidence 
rate found in the fourth quarter of 2011 (0.1) and the highest incidence rate found in 
the first and third quarter of 2013 (1.6) (Figure 1, Table 1). 
3.3. Microbiology and Antibiograms 
During the study period, 99 episodes of HD CRB were found of which five (5%) were 
 
 
Figure 1. Incidence rate of HD CRB in adult chronic HD patients, at Nordsjaellands Hospital 
compared with international studies [6] [7] [8] [9] The incidence rate of HD CRB episodes is 
shown per 1000 catheter-days for every quarter in the surveillance period (2010-2013). 
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Table 1. The calculated incidence (the number of HD CRB episodes per 1000 catheter-days) per 
quarter and per year in the study period. 
Year Quarter Episodes Catheter-days Incidence 
2010     
 1 10 8550 1.2 
 2 8 8554 0.9 
 3 6 7912 0.8 
 4 7 8188 0.9 
  31 33,204 0.9 
2011     
 1 7 7020 1.0 
 2 10 7150 1.4 
 3 4 7380 0.5 
 4 1 7380 0.1 
  22 28,930 0.8 
2012     
 1 4 8918 0.4 
 2 6 8918 0.7 
 3 4 9016 0.4 
 4 5 9016 0.6 
  19 35,868 0.5 
2013     
 1 8 4860 1.6 
 2 7 4914 1.4 
 3 8 4968 1.6 
 4 4 4968 0.8 
  27 19,710 1.4 
 
polymicrobial. We found 104 bacterial/fungal isolates (103 bacterial, 1 fungal). Among 
the 99 episodes of HD CRB, 70 (71%) were caused by gram-positive bacteria, 25 (25%) 
were caused by gram-negative bacteria, three (3%) were caused by both gram-positive 
and gram-negative bacteria and one episode (1%) was caused by yeast (Candida tropi-
calis). 
The most frequently isolated microorganisms were Staphylococcus aureus (33%), 
Coagulase-negative staphylococci (CoNS; 29%), and Enterobacter cloacae (8%) (Figure 
2). 
No significant difference in microbial isolates between men and women was ob-
served (Data not shown). 
Antibiograms for 92 (93%) episodes could be retrieved. No methicillin-resistant Sta-
phylococcus aureus (MRSA), extended spectrum beta-lactamase (ESBL)—producing 
bacteria, Carbapenemase producing organisms (CPO) or vancomycin-resistant entero-
coccus (VRE) were found. 
S. Kaarup et al. 
 
116 
 
Figure 2. Distribution (%) of microorganisms responsible for episodes of HD CRB in 
adult chronic HD patients, at Nordsjaellands Hospital from 2010-2013. A total of 99 
episodes of HD CRB occurred in the four-year study period with 104 isolated micro- 
organisms. Coagulase-negative staphylococci; CoNS: Staphylococcus epidermidis (17.3%), 
unspecified CoNS (8.7%), Staphylococcus hominis (1%), Staphylococcus capitis (1%), and 
Staphylococcus lugdunensis (1%). Enterobacteriaceae: Enterobacter cloacae (7.7%), Esche- 
richia coli (5.8%), Aeromonas caviae (1.9%), Klebsiella pneumoniae (1%), Klebsiella oxy- 
toca (1%), and Citrobacter koseri (1%). Enterococcus Spp.: Enterococcus faecalis (4.8%), 
and Enterococcus faecium (2.9%). Other: Streptococcus mitis (1.9%), Agrobacterium spe- 
cies (1%), Bacteroides fragilis (1%), and Micrococcus luteus (1%). Pseudomonas Spp: 
Pseudomonas aeruginosa (2.9%), and Stenotrophomonas maltophilia (1.9%). Yeast: Can- 
dida tropicalis (1%). 
3.4. Empiric Antimicrobials 
Empiric antimicrobials were given in 77 episodes (78%) and the overall efficacy was 
77%. Fourteen types of empiric antimicrobials from seven different classes (penicillins, 
cephalosporins, macrolides, glycopeptides, quinolones, carbapenems, and others (flu-
conazole and metronidazole)) were used in the study period; the most frequently used 
were cefuroxime (35 episodes) and vancomycin (27 episodes) (Table 2). 
Two or more types of empiric antimicrobials were administered in 44 (44%) epi-
sodes. 
4. Discussion 
In the present retrospective quality study of bacteremia in chronic HD patients, the 
mean incidence rate of HD CRB at NOH was 0.9 episodes/1000 catheter-days, which is 
low compared with that found in international studies [6] [7] [8] [9] [19]. Due to dif-
ferences in methods and definitions, several international studies are not directly com-
parable with the present study. Some studies have investigated the incidence of HD 
CRB in dialysis patients with all types of CVCs, e.g. the acute single lumen catheters  
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Table 2. List of the types of empiric antimicrobials used and the number of episodes they were 
used in. 
Empiric Antimicrobials (Type) Count 
Cefuroxime 35 
Vancomycin 27 
Ciprofloxacin 18 
Dicloxacillin 14 
Meropenem 8 
Metronidazole 6 
Penicillin 6 
Gentamycin 5 
Amoxacillin/Clavulanate 3 
Flucloxacillin 2 
Piperacillin/Tazobactam 2 
Cephalexin 1 
Fluconazole 1 
Roxithromycin 1 
 
[19], while others have defined an HD CRB differently due to differences in national 
guidelines, different equipment or different means of data collection. Furthermore, 
many studies calculate the incidence in episodes per person-days or years, which can-
not be directly converted to the catheter-days, as used in the present study. 
One study, from 2014 in North America by Rosenblum et al. [19], reported a blood-
stream infection (BSI) rate of 0.81/1000 catheter-days in a catheter hygiene intervention 
group and a BSI rate of 1.04/1000 catheter-days in their matched control group. Rosen-
blum et al. defined two separate BSIs as two positive blood cultures with 21 days be-
tween blood draws, whereas the present study defined it as two positive blood cultures 
with 28 days between the draws. In another study from North America in 2014 by 
Moore et al. [6], the incidence of CRBSI in all dialysis patients with a tunneled cuffed 
catheter was reported to be 0.45/1000 catheter-days for a patient group treated with an 
antibiotic lock solution versus 1.68/1000 catheter-days for the same group treated with 
the standard heparin lock. The study defined a CRBSI according to criteria established 
by the Centers for Disease Control and Prevention (CDC), which is in accordance with 
the definition used in the present study. 
The incidence rate in the present study was continuously low during the four-year 
study period, but reached a maximum in the first and third quarter of 2013 (Figure 1, 
Table 1). This small increase in incidence rate could be explained by a remarkably low 
number of catheter-days in 2013 compared with the other three years in the study pe-
riod (Table 1). The low number could be due to a change in the hospital’s geographical 
up-take area in 2012, which reduced the number of HD patients at NOH.  
The most frequently isolated microorganisms in both men and women were Staphy-
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lococcus aureus and CoNS, which is in accordance with other studies [6] [9] [20] [21]. 
An unexpected finding was the relatively high prevalence of bacteremic episodes 
caused by gram-negative bacteria (27%). However, the results of this surveillance pro-
gram largely follow those of recent studies [4] [8] [11] [20]. Alexandraki et al. investi-
gated the five-year pattern of microorganisms causing bacteraemias in HD patients 
with an HD catheter and found a significant increase in the incidence of single gram- 
negative organisms and polymicrobial bacteremia [21]. This trend might be due to an 
increasing degree of immunodeficiency in the dialysis patients or a failed empiric anti-
biotic policy, which focuses only on treating the expected gram-positive microorgan-
isms. 
During the surveillance period, the most frequently used empiric antimicrobials were 
cefuroxime and vancomycin, with an overall empiric treatment efficacy of 77%. Nota-
bly, cefuroxime was recommended as the empiric antibiotic treatment of sepsis without 
known focus at NOH in the study period. The recommendation was changed in 2014. 
In a recent Danish study of bacteremia by Boel et al. [22], an efficacy of empirical an-
timicrobial treatment of minimum 90% was suggested as acceptable; however, this 
study differed significantly from the present study as it comprised mostly community- 
acquired infections and only few patients with an HD catheter. Accordingly, we con-
sider an efficacy of empiric antimicrobials of 77% as acceptable. 
In contrast to several other studies, we did not find any MRSA, ESBL-producing 
bacteria, CPO or VRE [6] [9] [20] [21] [23]. In general, Denmark has a low level of an-
tibiotic resistance compared with many other countries [24]. 
A well-organized prevention program including surveillance as well as engaging pa-
tients and staff in preventive strategies has been reported to have a pronounced benefi-
cial effect on the incidence of infections in dialysis units [25] [26] [27] [28] [29]. The 
relatively low average incidence rate of HD CRB found in this study is probably a result 
of the extensive prevention bundle approach found at NOH, consisting of a surveillance 
program, a vascular access group where dialysis nurses and nephrologists have a special 
focus on establishing the optimal vascular access for every HD patient, hand hygiene 
education and audits for both staff and patients and a special no-touch method devel-
oped in the daily work with the dialysis patients where no hands or gloves are in direct 
contact with the head of the dialysis catheter when connecting and disconnecting to the 
dialysis machine. 
Compared with the recommendations from the CDC [14], the infection prevention 
strategy at NOH follows eight of the nine recommendations. 
The ninth recommendation regarding application of antimicrobial ointment to the 
catheter exit-site during dressing changes is not a part of the local guidelines. 
This study is retrospective and observational in nature and therefore has its limita-
tions. 1) Due to the observational nature of the study, there is a risk of selection bias. 2) 
It is not always possible to definitively determine the source of a bacteremia from elec-
tronic patient records when a clinical examination of the patient cannot be performed. 
3) There may have been patients with HD CRB hospitalized outside the Department of 
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Cardiology, Nephrology and Endocrinology, NOH and thereby not included in this 
study, but it is considered to be a very few patients, if any. 
The strength of this study is that monitoring of CRB using the benefits of the Danish 
Civil Registration System has been routine for several years in the department, which 
makes the data, albeit retrospective, very robust. 
5. Conclusion 
In conclusion, the NOH infection prevention strategy seems to be successful resulting 
in a relatively low incidence rate of hemodialysis catheter-related bacteremia during the 
study period 2010-2013. The unexpected high proportion of gram-negative bacteria, 
however, raises the question as to whether future antimicrobial guidelines ought to 
cover both gram-positive and gram-negative bacteria. 
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